COMPANY PROFILE // THE 014 REPORT
Propanc Biopharma, Inc.
PPCB (Nasdaq) · Formerly: Propanc Health Group Corp
Assembled from 2 government sources in 5.8 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-10-29 and 1 more time (last 24 months).
- InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.
✓ SEC filings✓ LEI✓ State registrationpossible match✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no website, no lobbying registration on record.
Propanc Biopharma, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Camberwell, Victoria, Australia; listed as PPCB (Nasdaq).[source] It has filed 37 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-13.[source] Seraphix flags 1 item from these records: 8-K Item 3.01 filed.[source]
- red0
- amber1
- info1
- CLEAR26
- POSSIBLE MATCH0
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001517681 | source |
| LEI | 549300Q3HY827FNV8Y56 | source |
| EIN | 33-0662986 | source |
| Business address (SEC) | 302/6 BUTLER STREET, CAMBERWELL, VICTORIA, C3, 3124 | source |
Does not exist in the records we hold: UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-02-14 · in 85 days · Next 10-Q due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-06-25 · in 216 days · LEI next renewal (549300Q3HY827FNV8Y56)
- 2027-09-28 · in 311 days · Next 10-K due (period ended 2027-06-30; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-10-29 filing 8-K items 3.01 · SEC EDGAR
- 2026-10-21 filing DEF 14C · SEC EDGAR
- 2026-10-08 filing PRE 14C · SEC EDGAR
- 2026-10-05 filing Registration (S-1) · SEC EDGAR
- 2026-09-25 filing Annual report (10-K) · SEC EDGAR
- 2026-08-21 filing DEF 14C · SEC EDGAR
- 2026-08-05 filing PRE 14C · SEC EDGAR
- 2026-07-27 filing EFFECT · SEC EDGAR
- 2026-07-17 filing Registration (S-1) · SEC EDGAR
- 2026-07-14 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-05-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-20 filing EFFECT · SEC EDGAR
- 2026-04-16 filing CORRESP · SEC EDGAR
- 2026-04-15 filing UPLOAD · SEC EDGAR
- 2026-04-10 filing Registration (S-1) · SEC EDGAR
- 2026-03-31 filing DEF 14C · SEC EDGAR
- 2026-03-20 filing PRE 14C · SEC EDGAR
- 2026-03-19 filing PRE 14A · SEC EDGAR
- 2026-03-06 filing 424B3 · SEC EDGAR
- 2026-02-26 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-02-24 filing EFFECT · SEC EDGAR
- 2026-02-20 filing CORRESP · SEC EDGAR
- 2026-02-19 filing S-1/A · SEC EDGAR
- 2026-02-17 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-02-12 filing CORRESP · SEC EDGAR
- 2026-02-10 filing CORRESP · SEC EDGAR
- 2026-02-10 filing UPLOAD · SEC EDGAR
- 2026-02-02 filing Registration (S-1) · SEC EDGAR
- 2026-01-30 filing 424B3 · SEC EDGAR
170 earlier entries
- 2026-01-09 filing EFFECT
- 2026-01-07 filing 8-K items 3.01
- 2026-01-06 filing CORRESP
- 2026-01-05 filing UPLOAD
- 2025-12-30 filing Registration (S-1)
- 2025-12-29 filing DEF 14C
- 2025-12-10 filing PRE 14C
- 2025-11-14 filing Quarterly report (10-Q)
- 2025-11-10 filing 8-K items 3.02,5.03,9.01
- 2025-10-14 filing 8-K items 1.01,9.01
- 2025-09-29 filing Annual report (10-K)
- 2025-08-19 officer change 8-K items 1.01,5.02,8.01,9.01
- 2025-08-18 filing 424B3
- 2025-08-18 filing 424B4
- 2025-08-14 filing CERT
- 2025-08-13 filing EFFECT
- 2025-08-13 filing 8-A12B
- 2025-08-13 officer change 8-K items 5.02
- 2025-08-12 filing CORRESP
- 2025-08-12 filing CORRESP
- 2025-07-31 filing CORRESP
- 2025-07-31 filing CORRESP
- 2025-07-30 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-07-29 filing CORRESP
- 2025-07-29 filing CORRESP
- 2025-07-28 filing S-1/A
- 2025-07-24 filing CORRESP
- 2025-07-24 filing CORRESP
- 2025-07-22 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-06-27 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-06-18 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-06-02 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-05-30 filing S-1/A
- 2025-05-15 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-04-25 filing S-1/A
- 2025-04-21 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-04-08 filing S-1/A
- 2025-04-02 filing S-1/A
- 2025-03-31 filing S-1/A
- 2025-03-18 filing 8-K items 1.01,2.03,3.02,9.01
- 2025-02-14 filing Quarterly report (10-Q)
- 2025-02-12 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-12-20 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-12-06 filing 8-K items 1.01,2.03,9.01
- 2024-11-14 filing Quarterly report (10-Q)
- 2024-11-06 filing UPLOAD
- 2024-10-30 filing Registration (S-1)
- 2024-09-30 filing Annual report (10-K)
- 2024-09-27 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-08-30 filing 8-K items 1.01,2.03,9.01
- 2024-08-22 filing DEF 14C
- 2024-08-15 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-08-08 filing PRE 14C
- 2024-08-07 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-07-02 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-06-21 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-06-13 filing 8-K/A items 1.01,2.03,3.02,9.01
- 2024-06-12 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-06-05 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-05-16 filing 8-K items 1.01,2.03,9.01
- 2024-05-15 filing Quarterly report (10-Q)
- 2024-04-22 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-04-10 filing 8-K items 8.01,9.01
- 2024-03-11 filing 8-K items 1.01,2.03,3.02,9.01
- 2024-02-20 filing Quarterly report (10-Q)
- 2024-02-14 filing NT 10-Q
- 2023-12-15 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-12-07 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-11-14 filing Quarterly report (10-Q)
- 2023-11-03 filing D
- 2023-10-30 filing 8-K items 8.01
- 2023-10-26 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-10-26 filing D
- 2023-10-17 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-10-17 filing 424B4
- 2023-10-12 filing EFFECT
- 2023-10-10 filing CORRESP
- 2023-10-10 filing S-1/A
- 2023-10-06 filing S-1/A
- 2023-09-28 filing Annual report (10-K)
- 2023-08-31 filing D
- 2023-08-31 filing D
- 2023-08-30 filing D
- 2023-08-29 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-08-21 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-08-16 filing D
- 2023-08-15 filing UPLOAD
- 2023-08-15 filing D
- 2023-08-11 filing Registration (S-1)
- 2023-08-08 filing 8-K items 1.01,1.02,2.03,3.02,9.01
- 2023-07-26 filing 8-K items 1.01,3.02,9.01
- 2023-07-12 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-05-15 filing Quarterly report (10-Q)
- 2023-05-15 filing 8-K items 1.01,2.03,2.04,3.02,9.01
- 2023-05-05 filing 8-K items 3.03,5.03,9.01
- 2023-04-04 filing 424B3
- 2023-03-27 filing EFFECT
- 2023-03-24 filing POS AM
- 2023-03-17 filing 8-K items 5.03,9.01
- 2023-02-22 filing 8-K items 8.01
- 2023-02-21 filing 8-K items 1.01,2.03,3.02,9.01
- 2023-02-10 filing Quarterly report (10-Q)
- 2022-11-14 filing Quarterly report (10-Q)
- 2022-11-01 officer change 8-K items 5.02,9.01
- 2022-10-12 filing 8-K items 1.01,2.03,3.02,9.01
- 2022-10-05 filing DEF 14C
- 2022-09-28 filing Annual report (10-K)
- 2022-09-27 filing 8-K items 1.01,2.03,3.02,9.01
- 2022-09-23 filing PRE 14C
- 2022-08-18 filing 8-K items 1.01,2.03,3.02,9.01
- 2022-07-11 filing 8-K items 5.03,5.07,9.01
- 2022-07-07 filing 8-K items 1.01,2.03,3.02,9.01
- 2022-06-09 filing DEF 14C
- 2022-05-27 filing PRE 14C
- 2022-05-18 filing 8-K items 1.01,2.03,3.02,9.01
- 2022-05-16 filing Quarterly report (10-Q)
- 2022-04-18 filing 8-K items 1.01,2.03,3.02,9.01
- 2022-04-01 filing 8-K items 1.01,2.03,3.02,9.01
- 2022-03-10 filing 8-K items 1.01,2.03,3.02,9.01
- 2022-02-22 filing 424B3
- 2022-02-14 filing Quarterly report (10-Q)
- 2022-02-11 filing EFFECT
- 2022-02-10 filing CORRESP
- 2022-02-10 filing S-1/A
- 2022-02-09 filing UPLOAD
- 2022-02-03 filing Registration (S-1)
- 2022-01-14 filing EFFECT
- 2022-01-10 filing POS AM
- 2022-01-10 filing 8-K items 1.01,2.03,3.02,9.01
- 2021-12-13 filing 8-K items 1.01,2.03,3.02,9.01
- 2021-12-07 filing 8-K items 1.01,3.02,9.01
- 2021-12-01 filing 8-K items 1.01,2.03,3.02,9.01
- 2021-11-12 filing Quarterly report (10-Q)
- 2021-10-27 filing 8-K items 1.01,2.03,3.02,9.01
- 2021-09-28 filing Annual report (10-K)
- 2021-09-28 filing 8-K items 1.01,2.03,3.02,9.01
- 2021-08-25 filing 8-K items 1.01,2.03,3.02,9.01
- 2021-08-18 officer change 8-K items 1.01,3.02,5.02,9.01
- 2021-05-14 filing Quarterly report (10-Q)
- 2021-03-19 filing 8-K items 1.01,2.03,3.02,9.01
- 2021-02-12 filing Quarterly report (10-Q)
- 2021-01-11 filing 8-K items 1.01,2.03,3.02,9.01
- 2020-12-30 officer change 8-K items 5.02,9.01
- 2020-12-16 filing 8-K items 1.01,2.03,3.02,9.01
- 2020-12-07 filing 8-K items 1.01,2.03,3.02,9.01
- 2020-11-19 filing 8-K items 3.03,5.03,9.01
- 2020-11-16 filing Quarterly report (10-Q)
- 2020-11-12 filing EFFECT
- 2020-11-10 filing CORRESP
- 2020-11-03 filing CORRESP
- 2020-11-03 filing S-1/A
- 2020-10-23 filing UPLOAD
- 2020-10-14 filing S-1/A
- 2020-10-01 filing Annual report (10-K)
- 2020-09-29 filing NT 10-K
- 2020-08-13 filing S-1/A
- 2020-08-13 filing CORRESP
- 2020-08-06 filing UPLOAD
- 2020-08-05 filing DEF 14C
- 2020-07-30 filing UPLOAD
- 2020-07-22 filing CORRESP
- 2020-07-22 filing PRER14C
- 2020-07-17 filing UPLOAD
- 2020-07-17 filing S-1/A
- 2020-07-16 filing CORRESP
- 2020-07-13 filing UPLOAD
- 2020-07-02 filing PRER14C
- 2020-07-02 filing CORRESP
- 2020-06-26 filing CORRESP
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-13 (within 30 days) 10-Q filed
- 2026-10-29 (within 30 days) 8-K filed: Item 3.01 delisting notice
- 2026-10-21 (older) DEF 14C filed
- 2026-10-08 (older) PRE 14C filed
- 2026-10-05 (older) S-1 filed
- 2026-09-25 (older) 10-K filed
- 2026-08-21 (older) DEF 14C filed
- 2026-08-05 (older) PRE 14C filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:PPCB The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
1 possible match held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1517681 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | PPCB / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 549300Q3HY827FNV8Y56 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 549300Q3HY827FNV8Y56) | GLEIF |
| EIN | 330662986 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001517681 | SEC EDGAR / IRS |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2026-06-30) | -$18,862,710 | 2026-06-30 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 23:55 UTC | Report an error |
| Total assets (at 2026-06-30) | $12,779,912 | 2026-06-30 | 10-K, XBRL Assets | as filed | 2026-11-21 23:55 UTC | Report an error |
| Stockholders' equity (at 2026-06-30) | $9,401,661 | 2026-06-30 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 23:55 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 23:55 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 23:55 UTC | Report an error |
| State of incorporation | DE | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 23:55 UTC | Report an error |
| Fiscal year end (MMDD) | 0630 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 23:55 UTC | Report an error |
| Business address | 302/6 BUTLER STREET, CAMBERWELL, VICTORIA, C3, 3124 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 23:55 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 23:55 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2026-06-30) | -$5,682,635 | 2026-06-30 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 23:55 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2026-06-30) | $4,933 | 2026-06-30 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 23:55 UTC | Report an error |
| Long-term debt (at 2025-06-30) | $537,921 | 2025-06-30 | 10-K, XBRL LongTermDebt | as filed | 2026-11-21 23:55 UTC | Report an error |
| Form D total offering amount (D filed 2023-11-03) | $40,000 | 2023-11-03 | D | as filed | 2026-11-21 23:55 UTC | Report an error |
| Form D total amount sold (D filed 2023-11-03) | $40,000 | 2023-11-03 | D | as filed | 2026-11-21 23:55 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2023-11-03 | D | as filed | 2026-11-21 23:55 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2023-11-03 | D | as filed | 2026-11-21 23:55 UTC | Report an error |
| Form D date of first sale | 2023-10-20 | 2023-11-03 | D | as filed | 2026-11-21 23:55 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001493152-26-051699
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$8,588,159 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001493152-26-051699 | 2026-11-21 23:55 UTC | Report an error |
| Interest expense | $18,244 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001493152-26-051699 | 2026-11-21 23:55 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-13 Filing 10-Q filed
- 2026-10-29 Filing 8-K filed: Item 3.01 delisting notice
- 2026-10-21 Filing DEF 14C filed
- 2026-10-08 Filing PRE 14C filed
- 2026-10-05 Filing S-1 filed
- 2026-09-25 Filing 10-K filed
- 2026-08-21 Filing DEF 14C filed
- 2026-08-05 Filing PRE 14C filed
- 2026-07-27 Filing EFFECT filed
- 2026-07-17 Filing S-1 filed
- 2026-07-14 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-05-14 Filing 10-Q filed
- 2026-04-20 Filing EFFECT filed
- 2026-04-16 Filing CORRESP filed
- 2026-04-15 Filing UPLOAD filed
- 2026-04-10 Filing S-1 filed
- 2026-03-31 Filing DEF 14C filed
- 2026-03-20 Filing PRE 14C filed
- 2026-03-19 Filing PRE 14A filed
- 2026-03-06 Filing 424B3 filed
- 2026-02-26 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-02-24 Filing EFFECT filed
- 2026-02-20 Filing CORRESP filed
- 2026-02-19 Filing S-1/A filed
- 2026-02-17 Filing 10-Q filed
8-K item text, as filed (excerpts)
- 2026-10-29 8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On October 23, 2026, Propanc Biopharma, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per share, and, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days prior to October 21, 2026, the Company no longer met this requirement. Normally, a… the 8-K · retrieved 2026-11-21 23:55 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- PROPANC BIOPHARMA, INC. · LEI 549300Q3HY827FNV8Y56 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
State licences (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPROPANC BIOPHARMA, INC. · exact legal name · sx:elic:ctcred:1754864 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1517681.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001517681. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.